HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 20, 14465-14473, May 19, 2006

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 281/20/14465    most recent M600457200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bellodi, C. Articles by Salomoni, P. Search for Related Content PubMed PubMed Citation Articles by Bellodi, C. Articles by Salomoni, P. Social Bookmarking                      What's this?

Cytoplasmic Function of Mutant Promyelocytic Leukemia (PML) and PML-Retinoic Acid Receptor-^*

Cristian Bellodi, Karin Kindle^¶, Francesca Bernassola^||, David Dinsdale, Andrea Cossarizza, Gerry Melino, David Heery^¶, and Paolo Salomoni¹

From the Medical Research Council Toxicology Unit, Leicester LE1 9HN, United Kingdom, ^¶School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, United Kingdom, ^||IDI-IRCCS Biochemistry Laboratory, Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy, and Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena 41100, Italy

The promyelocytic leukemia (PML) tumor suppressor of acute promyelocytic leukemia (APL) regulates major apoptotic and growth-suppressive pathways. In APL, PML is involved in a chromosomal translocation generating the PML-retinoic acid receptor- (RAR) fusion protein. Two missense mutations in the remaining PML alleles have been identified, which give rise to a truncated cytoplasmic PML protein (Mut PML). APL patients carrying these mutations display resistance to retinoic acid (RA) and very poor prognosis. Here we show that Mut PML associates with the cytoplasmic regions we refer to as PML-cytoplasmic bodies (PML-CBs). Mut PML interacts with PML-RAR in PML-CB and potentiates PML-RAR-mediated inhibition of RA-dependent transcription. Remarkably, Mut PML stabilizes PML-RAR and inhibits differentiation induced by pharmacological doses of RA. A mutant form of PML-RAR that accumulates in the cytoplasm inhibits RA-dependent transcription and differentiation, thus suggesting that cytoplasmic localization of PML-RAR may contribute to transformation. Finally, we show that the bcr3 PML-RAR form is predominantly cytoplasmic and accumulates in PML-CBs. Taken together, these findings reveal novel insights into the molecular mechanisms contributing to APL.

Received for publication, January 17, 2006

^* This work was supported by the Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. 1.

¹ To whom correspondence should be addressed. Tel.: 44-116-2525568; Fax: 44-116-2525616; E-mail: ps90{at}le.ac.uk.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				X. Ye, B. Zerlanko, R. Zhang, N. Somaiah, M. Lipinski, P. Salomoni, and P. D. Adams Definition of pRB- and p53-Dependent and -Independent Steps in HIRA/ASF1a-Mediated Formation of Senescence-Associated Heterochromatin Foci Mol. Cell. Biol., April 1, 2007; 27(7): 2452 - 2465. [Abstract] [Full Text] [PDF]